British Journal of Cancer
This journal is devoted to publishing cutting edge discovery, translational and clinical cancer research across the broad spectrum of oncology.
Tepotinib in Asian patients with METex14 skipping NSCLC
VISION, the largest study of a MET inhibitor for rare NSCLC with METex14 skipping mutations, shows tepotinib's efficacy and safety in Asian patients align with overall results. It provides the first health-related quality of life assessment for this group, supporting once-daily tepotinib treatment.